Pre-earnings options volume in Biomea Fusion (BMEA) is normal with calls leading puts 4:1. Implied volatility suggests the market is anticipating a move near 22.0%, or 0c, after results are released. Median move over the past eight quarters is 4.6%.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BMEA:
- Biomea Fusion Reports Positive Phase 2 T1D Trial Results
- Biomea Fusion announces positive 52-week results from phase 2 COVALENT-112 trial
- Biomea Fusion Advances Phase 2 Add-On Therapy Trial in Ozempic-Treated Diabetes
- Biomea Fusion Advances Mid‑Stage Diabetes Trial, Adding a New Angle to the BMEA Investment Story
- Biomea Fusion doses first patient in COVALENT-211, COVALENT-212 trials